Background American cutaneous leishmaniasis (ACL) is a complicated disease producing
about 67.000 new cases per year. The severity of the disease depends on the parasite …

The authors report a case of mucocutaneous leishmaniasis in a 45-year-old patient who was
unsuccessfully treated with pentavalent antimonial for 30 days. After 10 days from the initial …

The favorable outcome of the treatment of a disease is influenced by the adherence to
therapy. Our objective was to assess factors associated with adherence to treatment of …

Background Although high dose of antimony is the mainstay for treatment of American
cutaneous leishmaniasis (ACL), ongoing major concerns remain over its toxicity. Whether or …

BACKGROUND American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease
that presents with cutaneous (CL) and mucosal (ML) clinical forms. ATL treatment aims at …

The clinical diagnosis and laboratory identification of Leish‐mania brazilicnsis braziliensis, a
parasitic disease affecting the upper aerodigestive tract, is difficult. A retrospective computer …

Background Meglumine antimoniate (MA) remains the main treatment for cutaneous
leishmaniasis (CL). Uncontrolled studies suggest that intralesional MA (IL-MA) may be …

Cutaneous leishmaniasis (CL) by Leishmania braziliensis is associated with decreasing
cure rates in Brazil. Standard treatment with pentavalent antimony (Sb v) cures only 50–60 …

Abstract Colombian patients with New World cutaneous leishmaniasis were treated with a
combination of a topical formulation (15% paromomycin sulfate/5% methylbenzethonium …

Azithromycin was compared with meglumine antimoniate for treatment of patients with
cutaneous leishmaniasis. Patients were randomized to receive oral azithromycin, 500 …